Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended	110 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Mar. 31, 2012	Jun. 30, 2012	Jun. 30, 2011	Sep. 30, 2011	Jun. 30, 2012	Sep. 30, 2010
Stock-Based Compensation (Textual) [Abstract]
Options granted and outstanding to purchase	1,606,094			1,606,094		729,096	1,606,094	812,334
Options granted				924,500	0	20,000
Stock-based compensation expense				$ 837,188	$ 1,078,951
Stock-based compensation expense in discontinued operations				0	27,519
Provision for income taxes			0
Fair value of the options granted				3,505,912	62,964
Intrinsic value of the options exercised				0
Stock options exercised				(4,583)	0	(2,699)
Weighted average period to recognize pre-tax compensation expense				3 years 2 months 12 days		2 years 8 months 12 days
Calando Pharmaceuticals, Inc [Member]
Stock-Based Compensation (Textual) [Abstract]
Options granted					0
Fair value of the options granted				33,690
Pre-tax compensation expense	72,876			72,876			72,876
Arrowhead [Member]
Stock-Based Compensation (Textual) [Abstract]
Pre-tax compensation expense	$ 3,547,601			$ 3,547,601			$ 3,547,601
2000 Stock Option Plan [Member]
Stock-Based Compensation (Textual) [Abstract]
Share reserve for issuance	153,200			153,200		0	153,200
Options granted and outstanding to purchase	153,200			153,200			153,200
2004 Equity Incentive Plan [Member]
Stock-Based Compensation (Textual) [Abstract]
Share reserve for issuance	1,965,860			1,965,860			1,965,860
Options granted and outstanding to purchase	1,201,694			1,201,694			1,201,694
Options granted				660,000